WithdrawnNCT05427981
Anti-suicidal Effects of Buprenorphine In Depressed Individuals
Medication studyAges 18–65United StatesDepression
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 10, 2022
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- New York State Psychiatric Institute
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05427981
- Official title
Show the full official title
Functional Brain Mechanisms Underlying the Anti-Suicidal Effects of Low-dose Buprenorphine in Major Depression
Recruitment & locations
WithdrawnNew York
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is New York State Psychiatric Institute, a research institute.
Does this study involve medication?
Yes. The study involves medication, including Belbuca Buccal Product.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as withdrawn.
